Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CRYO CELL INTERNATIONAL INC (CCEL)

Cryo-Cell receives NYSE American notice of noncompliance with listing standards

Negative Impact 3 of 5 legal/regulatory Written later

Cryo-Cell International received a March 9, 2026 notice from NYSE American stating it does not meet Section 1003(a) of the NYSE American Company Guide, citing a stockholders' deficit as of November 30, 2025 and net losses in two of its three most recent fiscal years. The notice has no immediate effect on trading, and the company plans to submit a compliance plan by April 8, 2026, but there is no assurance NYSE American will accept the plan or that compliance will be regained.

Key points

  • NYSE American notice received March 9, 2026, under Section 1003(a) of the Company Guide
  • Cited a stockholders' deficit as of November 30, 2025, and net losses in two of the three fiscal years ended November 30, 2023, 2024 and 2025
  • Common stock continues to trade as CCEL; compliance plan due by April 8, 2026; if accepted, the company is typically granted up to 18 months from receipt of the notice

The filing

CompanyCRYO CELL INTERNATIONAL INC (CCEL)
Form8-K, current report
Filed with the SECMar 12, 2026, 5:00 PM ET
Accession number0001193125-26-104392

Items reported: 3.01 Delisting / Listing Rule Notice7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:29 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.